Human Complement Component C5/C5a Antibody

Catalog # Availability Size / Price Qty
N-Acetyl-beta -D-Glucosamini-dase Release Induced by Complement Component C5a and Neutralization by Human Complement Component C5a Antibody.
1 Image
Product Details
Citations (9)
Supplemental Products

Human Complement Component C5/C5a Antibody Summary

Species Reactivity
Detects human Complement Component C5/C5a in ELISAs and Western blots. In sandwich immunoassays, detects human Complement Component C5a by itself or in the context of Complement Component C5. In Western blots, this antibody does not cross-react with recombinant human Complement Component C2, recombinant mouse (rm) Complement Component C3d, or rmComplement Component C5a.
Monoclonal Mouse IgG1 Clone # 295003
Protein A or G purified from hybridoma culture supernatant
E. coli-derived recombinant human Complement Component C5a
Accession # P01031
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.


Recommended Concentration
Western Blot
1 µg/mL
Recombinant Human Complement Component C5a (Catalog # 2037-C5)
under non-reducing conditions only

Human Complement Component C5/C5a Sandwich Immunoassay

Recommended Concentration
ELISA Capture (Matched Antibody Pair)
2-8 µg/mL 

Use in combination with:

Detection Reagent: Human Complement Component C5/C5a Biotinylated Antibody (Catalog # BAM20371)

Standard: Recombinant Human Complement Component C5a Protein (Catalog # 2037-C5)

Measured by its ability to neutralize Complement Component C5a-induced N-acetyl-beta -D-glucosaminidase release in the dibutyryl cyclic-AMP differentiated U937 human histiocytic lymphoma cell line. Gerard, NP and Gerard, C. (1990) Biochemistry 29:9274. The Neutralization Dose (ND50) is typically 0.04-0.12 µg/mL in the presence of 10 ng/mL Recombinant Human Complement Component C5a and cytochalasin‑B.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization N-Acetyl-beta -D-Glucosamini-dase Release Induced by Complement Component C5a and Neutralization by Human Complement Component C5a Antibody. View Larger

N-Acetyl-beta -D-Glucosamini-dase Release Induced by Complement Component C5a and Neutralization by Human Complement Component C5a Antibody. Recombinant Human Complement Component C5a (Catalog # 2037-C5) induces N-acetyl-beta -D-glucosaminidase release in the the dibutyryl cyclic-AMP differentiated U937 human histiocytic lymphoma cell line in a dose-dependent manner (orange line). N-Acetyl-beta -D-Glucosamin-idase Release elicited by Recombinant Human Complement Component C5a (10 ng/mL) is neutralized (green line) by increasing concen-trations of Mouse Anti-Human Complement Component C5a Monoclonal Antibody (Catalog # MAB2037). The ND50 is typically 0.04-0.12 µg/mL in the presence of cytochalasin-B.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Preparation and Storage

Reconstitute at 0.5 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Complement Component C5/C5a

Human complement component C5a (C5a) is an enzymatically generated glycoprotein that belongs to a family of structurally and functionally related proteins known as anaphylatoxins. C5a is a 74 amino acid (aa) peptide that is created by the activity of C5a convertase on the C5 alpha -chain (1, 2). Human C5a has four alpha -helices plus three intrachain disulfide bonds that create a triple loop structure (3). In serum, proteolytic processing removes the C-terminal arginine, creating a low activity C5a desArg74 molecule (1). Human C5a is 60% and 54% aa identical to mouse and rat C5a, respectively. C5a binds to a signaling G-protein coupled receptor (C5aR/CD88) and a non-signaling GPCR termed C5L2 (4). Activation of Cd88 results in neutrophil chemotaxis and endothelial cell activation (1, 5). It also triggers an oxidative burst in macrophages and neutrophils, and induces release of histamine in basophils and mast cells.

  1. Gerard, C. and N.P. Gerard (1994) Annu. Rev. Immunol. 12:775.
  2. DiScipio, R.G. et al. (1983) J. Biol. Chem. 258:10629.
  3. Huber-Lang, M.S. et al. (2003) J. Immunol. 170:6115.
  4. Okinaga, S. et al. (2003) Biochemistry 42:9406.
  5. Gerard, N.P. and C. Gerard (2002) Curr. Opin. Immunol. 14:705.
Entrez Gene IDs
727 (Human); 15139 (Mouse)
Alternate Names
C5; C5a;C5b;C5D;Complement C5;CPAMD4;ECLZB; Complement Component C5/C5a

Product Datasheets

You must select a language.


Citations for Human Complement Component C5/C5a Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

9 Citations: Showing 1 - 9
Filter your results:

Filter by:

  1. FGF19‐Induced Inflammatory CAF Promoted Neutrophil Extracellular Trap Formation in the Liver Metastasis of Colorectal Cancer
    Authors: Chen Li, Tianli Chen, Jialiang Liu, Yue Wang, Chunhuan Zhang, Lu Guo et al.
    Advanced Science
  2. Altered plasma protein profiles in genetic FTD - a GENFI study
    Authors: Ullgren, A;Öijerstedt, L;Olofsson, J;Bergström, S;Remnestål, J;van Swieten, JC;Jiskoot, LC;Seelaar, H;Borroni, B;Sanchez-Valle, R;Moreno, F;Laforce, R;Synofzik, M;Galimberti, D;Rowe, JB;Masellis, M;Tartaglia, MC;Finger, E;Vandenberghe, R;de Mendonça, A;Tirabosch, P;Santana, I;Ducharme, S;Butler, CR;Gerhard, A;Otto, M;Bouzigues, A;Russell, L;Swift, IJ;Sogorb-Esteve, A;Heller, C;Rohrer, JD;Månberg, A;Nilsson, P;Graff, C;Genetic Frontotemporal Dementia Initiative (GENFI), ;
    Molecular neurodegeneration
    Species: Human
    Sample Types: Plasma
    Applications: Bioassay
  3. The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare
    Authors: CR Toy, H Song, HN Nagaraja, J Scott, J Greco, X Zhang, CY Yu, JA Tumlin, BH Rovin, LA Hebert, DJ Birmingham
    Kidney international reports, 2021-06-09;6(8):2105-2113.
    Species: Human
    Sample Types: Plasma
    Applications: ELISA Capture
  4. Therapeutic Hypothermia Inhibits the Classical Complement Pathway in a Rat Model of Neonatal Hypoxic-Ischemic Encephalopathy
    Authors: TA Shah, HK Pallera, CL Kaszowski, WT Bass, FA Lattanzio
    Frontiers in Neuroscience, 2021-02-12;15(0):616734.
    Species: Rat
    Sample Types: Plasma
    Applications: ELISA Capture
  5. Establishing a Case for Anti-complement Therapy in Membranous Nephropathy
    Authors: I Ayoub, JP Shapiro, H Song, XL Zhang, S Parikh, S Almaani, S Madhavan, SV Brodsky, A Satoskar, C Bott, L Yu, M Merchant, J Klein, JM Mejia-Vile, T Nadasdy, D Birmingham, BH Rovin
    Kidney international reports, 2020-12-13;6(2):484-492.
    Species: Human
    Sample Types: Urine
    Applications: ELISA Capture
  6. Attenuation of Staphylococcus aureus-Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb.
    Authors: Georgoutsou-Spyridonos M, Ricklin D, Pratsinis H, Perivolioti E, Pirmettis I, Garcia B, Geisbrecht B, Foukas P, Lambris J, Mastellos D, Sfyroera G
    J Immunol, 2015-09-04;195(8):3946-58.
    Species: Human
    Sample Types: Plasma
    Applications: ELISA Development (Capture)
  7. Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies.
    Authors: Ramadass, Mahalaks, Ghebrehiwet, Berhane, Smith, Richard, Kew, Richard
    J Immunol, 2013-12-23;192(3):1220-30.
    Species: Human
    Sample Types: Serum
    Applications: ELISA Development (Capture)
  8. C5a and TNF-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome.
    Authors: Kambas K, Markiewski MM, Pneumatikos IA, Rafail SS, Theodorou V, Konstantonis D, Kourtzelis I, Doumas MN, Magotti P, Deangelis RA, Lambris JD, Ritis KD
    J. Immunol., 2008-06-01;180(11):7368-75.
    Species: Human
    Sample Types: BALF
    Applications: ELISA Development
  9. Abnormal Complement Activation and Inflammation in the Pathogenesis of Retinopathy of Prematurity
    Authors: Sonika Rathi, Subhadra Jalali, Satish Patnaik, Shahna Shahulhameed, Ganeswara R. Musada, Divya Balakrishnan et al.
    Frontiers in Immunology


No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Reviews for Human Complement Component C5/C5a Antibody

There are currently no reviews for this product. Be the first to review Human Complement Component C5/C5a Antibody and earn rewards!

Have you used Human Complement Component C5/C5a Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review